Corporate funding and the economic recovery: why UK businesses should be optimistic about the months ahead

In this quick-take article, Ross Walker dives into the latest UK corporate funding & sentiment data and highlights several key reasons why businesses should be optimistic about normalising conditions as the country slowly – but surely – escapes the pandemic’s grip.

The economic normalisation continues

Broad money supply growth (excluding the shadow banking system) slowed in February from 1.2% month-on-month to 0.6%. That would normally be a sign of a slowdown in economic activity but at this juncture, against the backdrop of an economic lockdown, we regard this slower build-up of cash balances – much of which is ‘forced savings’ – as a positive sign. This lends further weight to our view that an exuberant consumption-led recovery, driven by pent-up demand and fuelled by lockdown-induced savings, is in the offing (see our latest economic quarterly for more on this).

The UK housing market also remains buoyant. The Stamp Duty cut and changes in living preferences appear to outweigh the dead hand of social distancing, with 88 thousand new mortgage approvals in February, slipping modestly on a monthly basis but still some way above the pre-crisis 3-year average of 66 thousand. Royal Institution of Chartered Surveyors (RICS) survey data signals renewed strength in the coming months – gains in expected prices and new buyer enquiries.

Corporate lending: a more stable pattern is emerging

Against that backdrop, corporate funding appears to be normalising. Funding for non-financial private corporates (PNFC) staged a partial but broadly-based recovery in February (see chart below), rising 0.3% from the month before after a 0.6% monthly decline in January – and pushing corporate lending to a 7-month high.

PNFC net financing (£ billions per month)

Sources: Bank of England, NatWest Markets

The detailed breakdown of UK corporate funding in March shows an increase in financing across most sources: bank lending (+£1.9 billion), corporate bonds (+£0.2 billion) and equity issuance (+£1.1 billion). Only net commercial paper (CP) funding declined in March (-£0.5 billion). But on aggregate, following a surge in financing during the early stages of the pandemic, a more stable pattern of UK corporate sector funding appears to be emerging, potentially marking an important turnaround.

Both capex and M&A are driving funding: is this a turning point?

Corporates have reason to be cautiously optimistic. The Bank of England’s (BoE) latest Credit Conditions Survey (CCS) show notable improvements in the expected supply of, and demand for, credit, a sign that credit conditions continue to improve. Financing for mergers & acquisitions (M&A) purposes, at decade-long highs, also remains buoyant across a range of sectors as opportunistic buyers & eager sellers combine with an abundance of capital (thanks in part to ultra-loose monetary policy).

But it also shows a sizeable increase in corporate demand for funding to finance new capex – which reached multi-year highs despite remaining in negative territory overall (see chart below).

Bank of England Credit Conditions Survey: corporate demand for funding (net % balances)

Sources: Bank of England, NatWest Markets

In the months ahead, support measures included in the latest UK Budget should provide a boost to business investment, or at the very least front-load corporate spending. In general, we expect UK corporates to remain a little defensive as the economy slowly reopens. And because we think consumers will be the primary drivers of the economic recovery, corporate capex is likely to lag other growth components – like household consumption – over the next year or so. Nevertheless, the latest data show we may be reaching an important turning point as we escape the pandemic’s grip: corporate funding is starting to normalise, credit conditions are improving, and – crucially – businesses are starting to invest.

To speak with us about this article, get in touch with your NatWest Corporate & Institutional representative or contact us here.

This article has been prepared for information purposes only, does not constitute an analysis of all potentially material issues and is subject to change at any time without prior notice. NatWest Markets does not undertake to update you of such changes.  It is indicative only and is not binding. Other than as indicated, this article has been prepared on the basis of publicly available information believed to be reliable but no representation, warranty, undertaking or assurance of any kind, express or implied, is made as to the adequacy, accuracy, completeness or reasonableness of the information contained in this article, nor does NatWest Markets accept any obligation to any recipient to update or correct any information contained herein. Views expressed herein are not intended to be and should not be viewed as advice or as a personal recommendation. The views expressed herein may not be objective or independent of the interests of the authors or other NatWest Markets trading desks, who may be active participants in the markets, investments or strategies referred to in this article. NatWest Markets will not act and has not acted as your legal, tax, regulatory, accounting or investment adviser; nor does NatWest Markets owe any fiduciary duties to you in connection with this, and/or any related transaction and no reliance may be placed on NatWest Markets for investment advice or recommendations of any sort. You should make your own independent evaluation of the relevance and adequacy of the information contained in this article and any issues that are of concern to you.

This article does not constitute an offer to buy or sell, or a solicitation of an offer to buy or sell any investment, nor does it constitute an offer to provide any products or services that are capable of acceptance to form a contract. NatWest Markets and each of its respective affiliates accepts no liability whatsoever for any direct, indirect or consequential losses (in contract, tort or otherwise) arising from the use of this material or reliance on the information contained herein. However this shall not restrict, exclude or limit any duty or liability to any person under any applicable laws or regulations of any jurisdiction which may not be lawfully disclaimed.

NatWest Markets Plc. Incorporated and registered in Scotland No. 90312 with limited liability. Registered Office: 36 St Andrew Square, Edinburgh EH2 2YB. Authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and Prudential Regulation Authority. NatWest Markets N.V. is incorporated with limited liability in the Netherlands, authorised and regulated by De Nederlandsche Bank and the Autoriteit Financiële Markten. It has its seat at Amsterdam, the Netherlands, and is registered in the Commercial Register under number 33002587. Registered Office: Claude Debussylaan 94, Amsterdam, the Netherlands. Branch Reg No. in England BR001029. NatWest Markets Plc is, in certain jurisdictions, an authorised agent of NatWest Markets N.V. and NatWest Markets N.V. is, in certain jurisdictions, an authorised agent of NatWest Markets Plc. NatWest Markets Securities Japan Limited [Kanto Financial Bureau (Kin-sho) No. 202] is authorised and regulated by the Japan Financial Services Agency. Securities business in the United States is conducted through NatWest Markets Securities Inc., a FINRA registered broker-dealer (, a SIPC member ( and a wholly owned indirect subsidiary of NatWest Markets Plc.

Copyright 2022 © NatWest Markets Plc. All rights reserved.

scroll to top